April 5, 2017 — Siemens Healthineers announced that the U.S. Food and Drug Administration (FDA) has approved High Definition Breast Tomosynthesis. This unique form of digital breast tomosynthesis (DBT) includes new algorithms designed to deliver a heightened level of sensitivity to breast cancer detection and diagnosis over 2-D mammography alone.
High Definition Breast Tomosynthesis builds on the established DBT platform from Siemens Healthineers with what the company calls the industry’s widest tomo sweep of 50 degrees. Siemens also said it delivers images of exceptional clarity, and is the first solution approved for 3-D-only mammograms.
High Definition Breast Tomosynthesis incorporates new EMPIRE (Enhanced Multiple Parameter Iterative Reconstruction) technology, a combination of iterative and machine learning algorithms that provide a clearer, more concise 3-D reconstruction.
While EMPIRE technology has been approved as a 3-D-only exam, it also includes Insight 2-D and 3-D — what Siemens calls the industry’s first synthetic software-generated visualization of tomosynthesis volumes in both 2-D and 3-D. Insight 2-D allows breast imagers to obtain a 2-D image from the EMPIRE 3-D image set, providing them with a navigational support tool to their 3-D-only exams without subjecting patients to added dose. Insight 3-D adds new depth to the visualization of the breast anatomy.
High Definition Breast Tomosynthesis is available as an option on the company’s Mammomat Inspiration with Tomosynthesis Option digital mammography system.
For more information: www.usa.healthcare.siemens.com
April 18, 2024 
